Google
Trusted Resources: News & Events
Latest announcements and gatherings
Partnership to Ensure Supply of LentiGlobin, Potential Gene Therapy
Bluebird Bio extended a partnership with two divisions of Hitachi Chemical for the long-term development and manufacturing of LentiGlobin, its investigational gene therapy for sickle cell disease (SCD), and other potential and approved treatments.
The two subsidiaries — Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma — will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).
“It is our honor to support bluebird bio in the manufacture of their potentially transformative gene therapies, to the benefit of patients in both the United States and Europe, as the foundation for our collaboration to address this devastating disease,” Robert Preti, PhD, chief strategy officer at Hitachi Chemical Life Science Business Headquarters, said in a press release.
+myBinderRelated Content
-
UH Researcher Reports the Way Sickle Cells Form May Be Key to Stopping ThemUniversity of Houston associate professo...
-
NHLBI Stepping Up Efforts to Apprise SCD Patients of Therapies and TrialsWide interest in a CBS 60 Minutes story ...
-
‘I Have Sickle Cell, but Sickle Cell Doesn’t Have Me’: While Raising Awareness, Chicago Man, 25, Dies From...Elijah Powell was determined to live his...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
Individuals with Disabilities Education Act (IDEA)The U.S. Department of Education’s Ind...
-
Changing the Conversation for Sickle Cell Disease and Reshaping its FutureThis issue titled "Changing the Conversa...
-
Conquering The Curve, Inc.Conquering The Curve is an initiative th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.